|
市場調查報告書
2007年第1季的藥價、償還、處方最新動向
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2007
|
本報告已在2011年12月21日停止出版。
2007年第1季的全球主要藥品市場中，政治介入管理藥價及償付的程度提高。政府為了縮減醫療費用，製藥產業首當其衝。
專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. 總公司：Massachusetts State），針對2007年第1季藥價、償付、處方的最新動向進行調查分析，並系統整理調查結果後出版報告書 "Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2007"。
本報告書內容包括：2007年第1季美國、歐洲、日本藥價、償還、處方環境的主要事件、費用管控計畫概要、今後發展預測等。內容綱要摘記如下：
實施概要
介紹
美國
- 2005年美國醫療費用減少
- 2006年美國藥品市場的穩健成長
- 聯邦政府計畫的藥價調查
- Medicare Part D的擴大
- Medicare Part D相關政府的藥價交?壓力
- Medicaid的回饋
- 提高非專利藥品利用的方案
- 對非專利生物藥品的管制
- 藥品進口
法國
- 為靈活運用費用及創新藥物的政府運作架構
- 平行輸入
- 對肥胖治療的有限償付
- GlaxoSmithKline因採略奪性訂價而遭課處罰金
德國
- 藥品費用減少
- 實施新的醫療改革
- 製造商折扣增加
- 單日治療費用限制
義大利
- 對地區別參考價格主導權的顧慮
- 要求改變藥品政策的產業
西班牙
英國
- 藥價規範制度修正案
- 單一技術評價的新名單
- 處方費用調整
日本
圖
- 1970年至2005年美國的處方藥費用動向
- 美國處方藥費用的主要財源：2005年
- Medicare受惠者的處方藥適用範圍：2007年1月
Abstract
Introduction:
In the fi rst quarter of 2007, political intervention in drug pricing and
reimbursement in the world' s major pharmaceutical markets greatly increased.
In the United States, for example, a new Democratic majority in Congress is
intent on curbing the prices of branded medicines and facilitating the launch
of generic drugs. In the United Kingdom, a complete overhaul of the country' s
pricing and reimbursement system has been proposed. The goal in all major
pharmaceutical markets is to cut health care costs, and the pharmaceutical
industry is an easy target.
Questions Answered in This Spectrum Report:
- In January 2007, U.S. lawmakers proposed a series of bills to improve U.S.
consumers' access to lowpriced generic drugs, including biogenerics. Which
bills have been proposed, how much savings are they purported to offer, and
what are their chances of being made into law?
- According to the Centers for Medicare and Medicaid Services, the Medicare
Part D prescription drug benefit is saving benefi ciaries an average of $1,200
per year. On January 12, 2007, in a further attempt to lower drug prices, the
House of Representatives passed the Medicare Prescription Drug Price
Negotiation Act of 2007, which would empower the Department of Health and
Human Services to negotiate Medicare Part D drug prices. What is the
Congressional Budget Offi ce' s argument against this proposal?
- In February 2007, the United Kingdom' s Offi ce of Fair Trading (OFT)
published a highly critical review of the Pharmaceutical Price Regulation
Scheme, which controls the level of profi t companies may make on sales of
branded prescription drugs to the National Health Service. What were the OFT' s
criticisms, and what two options did the agency propose to better control
prescription drug prices?
- The announcement, in March 2007, by Japan' s Ministry of Health, Labor, and
Welfare that it is considering overhauling the national pricing and
reimbursement system has galvanized the international pharmaceutical industry,
which has long been critical of the system. What reforms is the Federation of
Pharmaceutical Manufacturers' Associations of Japan planning to propose?
Scope:
- First quarter news in 2007: major events in the pharmaceutical pricing,
reimbursement, and prescribing environment in the United States, Europe
(France, Germany, Italy, Spain, and the United Kingdom), and Japan.
- Cost-containment programs: legislation that has been proposed in the
United States and elsewhere to reduce drug expenditures and make medication
more affordable to patients.
- Outlook: our assessment of the implications of these events for the
pharmaceutical industry in the major markets under study.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- United States
- Slowdown in U.S. Health Care Spending in 2005
- Solid Growth in U.S. Pharmaceutical Market in 2006
- Increased Scrutiny of Drug Prices for Federal Programs
- Continued Growth in Medicare Part D Enrollment
- Pressure for Government Price Negotiations for Medicare Part D
- Prospect of Increased Medicaid Rebates
- Measures to Improve Access to Generic Drugs
- Regulation of Biogenerics
- Drug Importation
- France
- National Frame of Reference for the Good Use of Expensive and Innovative
Drugs
- Parallel Imports
- Obesity Therapy Qualifi es for Limited Reimbursement
- GlaxoSmithKline Fined for Predatory Pricing
- Germany
- Slowdown in Pharmaceutical Spending
- New Health Care Reforms Enacted
- Growth of Manufacturer Rebates
- Daily Cost-of-Therapy Limits
- Italy
- Concern over Regional Reference Pricing Initiatives
- Industry Calls for a Change in Pharmaceutical Policy
- Spain
- Implementation of New Reference Pricing System
- New System to Monitor Parallel Exports
- United Kingdom
- Proposal to Replace the Pharmaceutical Price Regulation Scheme
- New Candidates for Single Technology Appraisals
- Adjustments to Prescription Charges
- Japan
- Expected Reform of the Pricing and Reimbursement System
- Limited Level of Generics Substitution
- Outlook and Implications for the Pharmaceutical Industry
Figures
- 1. Evolution of Prescription Drug Expenditures in the United States in
Select Years from 1970 to 2005
- 2. Main Sources of Funding for U.S. Prescription Drug Expenditures, 2005
- 3. Medicare Benefi ciaries' Prescription Drug Coverage, January 2007
|
